Abstract
The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m2, the remaining with 500 mg/m2. We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.
| Original language | English |
|---|---|
| Journal | Oncology Reports |
| Volume | 12 |
| Issue number | 4 |
| Pages (from-to) | 767-771 |
| Number of pages | 5 |
| ISSN | 1021-335X |
| DOIs | |
| Publication status | Published - 10.2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)
Fingerprint
Dive into the research topics of 'Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver